Alembic Pharmaceuticals Ltd. Share Price

HBL Engineering Recent setup: broke out candidate

HBL Engineering Recent setup: broke out of a consolidation range and trendline with strong volume. Reference price: ₹775.30 Upside levels cited by JM Financial: ₹809 and ₹830 Risk level cited: ₹735 The broader market was weak on Sept 24, so a breakout should ideally be confirmed by volume rather than chased at the open. Other current breakout/momentum setups worth watching: Inventurus Knowledge Solutions: ₹1,868 → ₹2,050/₹2,150; SL ₹1,785. Alembic Pharma: ₹850 → ₹900/₹999; SL ₹786. Finolex Cables: ₹1,480 → ₹1,600; SL ₹1,400. Important: These are technical setups reported by analysts, not a guaranteed “tomorrow breakout.” For Monday, I'd wait for the first 15–30 minutes and look for price + volume confirmation.

See More

Alembic Pharma in Focus After USFDA EIR Clearance

Alembic Pharmaceuticals Limited (

) is in focus after the USFDA issued an Establishment Inspection Report (EIR) and closed the inspection of the company's bioequivalence facility in Vadodara, Gujarat. The development removes a regulatory overhang and reinforces the facility's compliance status. For pharmaceutical companies with exposure to the US market, regulatory clearances are closely watched as they support business continuity and future product opportunities. Alembic Pharmaceuticals derives a meaningful portion of its business from international generics and APIs, making USFDA-related developments important for investor sentiment. While the regulatory update is positive, the stock has yet to reflect a decisive directional move. Over the past two and a half months, Alembic Pharmaceuticals has largely traded within the ₹790–₹855 range, despite previously forming an Inverse Head & Shoulders pattern. The prolonged consolidation near the neckline suggests that market participants are awaiting a stronger trigger before committing to a sustained trend. A sustained move above ₹860, supported by rising volumes and preferably two consecutive daily closes above the level, could indicate strengthening momentum. On the downside, a break below ₹787 would weaken the recent higher-high, higher-low structure and warrant caution. The USFDA development is fundamentally positive, but the technical setup remains range-bound. For now, ₹860 on the upside and ₹787 on the downside remain the key levels that could determine the stock's next meaningful move. Disclosure: Neither I nor my family members hold any position in the mentioned scrip. This content is shared solely for informational and educational purposes and should not be construed as investment advice or a recommendation to buy or sell.

See More

Alembic Pharma Unit Clears US FDA Inspection Cleanly

: Alembic Pharmaceuticals’ Bioequivalence Facility in Gujarat has successfully completed a US FDA inspection with zero observations. The inspection was conducted over 11 days from August 31 to September 10, 2026. The US FDA issued Form 483 with no observations, indicating that no procedural or regulatory compliance issues were identified during the inspection. A clean inspection outcome is a positive regulatory development for Alembic Pharma as it reinforces the facility’s compliance standards and supports continued product development activities and ANDA filings for the US market. The outcome also reduces near-term regulatory uncertainty around the facility and supports the company’s ability to progress its US-focused product pipeline. While the inspection itself does not directly add revenue, maintaining a strong compliance track record is important for sustained US market opportunities. Stock Commentary – Alembic Pharmaceuticals APLLTD – HIGHLY POSITIVE (8/10): A zero-observation US FDA inspection strengthens confidence in Alembic Pharma’s regulatory compliance and supports uninterrupted product development and ANDA filings for the US market. The clean outcome reduces regulatory overhang for the facility.

See More

Alembic Pharma Delivers Strong Revenue Growth in Q1FY27

💊

reported Q1FY27 consolidated net profit of ₹170 crore, up from ₹154 crore in the corresponding quarter last year. Revenue increased sharply to ₹2,150 crore from ₹1,710 crore, while the EBITDA margin softened to 15.44% from 16.45% despite strong top-line growth.

See More

Update for investors of

is currently trading at Rs. 818.75, up by 4.30 points or 0.53% from its previous closing of Rs. 814.45 on the BSE. The scrip opened at Rs. 814.45 and has touched a high and low of Rs. 828.70 and Rs. 812.90 respectively. So far 6493 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1024.70 on 28-Jul-2025 and a 52 week low of Rs. 635.30 on 23-Mar-2026. Last one week high and low of the scrip stood at Rs. 841.35 and Rs. 790.35 respectively. The current market cap of the company is Rs. 16101.47 crore. The promoters holding in the company stood at 69.87%, while Institutions and Non-Institutions held 20.12% and 10.01% respectively. Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prucalopride Tablets, 1 mg and 2 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA Inc. Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg and 2 mg, have an estimated market size of $100 million for twelve months ending March 2026 according to IQVIA. Alembic has a cumulative total of 245 ANDA approvals (225 final approvals and 20 tentative approvals) from USFDA. Alembic Pharmaceuticals is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.

See More